Literature DB >> 16965422

European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey.

L Dubertret1, U Mrowietz, A Ranki, P C M van de Kerkhof, S Chimenti, T Lotti, G Schäfer.   

Abstract

BACKGROUND: EUROPSO (European Federation of Psoriasis Patient Associations) undertook a Europe-wide survey examining quality of life and patients' perspectives on treatment and their disease.
OBJECTIVES: To explore patients' perspectives of psoriasis on their lifestyle and well-being and to gain insight into the effectiveness of and satisfaction with currently available therapies for psoriasis.
METHODS: Self-administered questionnaires (n = 50,500) were mailed to members of psoriasis patient associations in Belgium, the Czech Republic, Finland, France, Germany, Italy and the Netherlands.
RESULTS: Responses were received from 18,386 patients (36%), of whom 17,990 had psoriasis. Mean age at onset of psoriasis was 30.5 years, 59% of respondents had self-reported moderate to severe psoriasis (3% or greater body surface area involvement) and 30% had been diagnosed with psoriatic arthritis. The mean Psoriasis Disability Index score was 12.2 (25% of the maximum score), increasing to 21 (44%) in patients with more than 10% body surface area involvement. The greatest impact was on activities of daily living, especially affecting clothing choice, bathing routine and sporting activities. Overall, 77% replied that psoriasis was a problem or a significant problem. While patients were satisfied with the information and care from their dermatologist (40% highly satisfied), available treatment options were less satisfactory, with over 70% reporting only low to moderate satisfaction.
CONCLUSIONS: This is the largest survey of people with psoriasis in Europe and shows that psoriasis has a profound impact on quality of life.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16965422     DOI: 10.1111/j.1365-2133.2006.07405.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  48 in total

Review 1.  Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.

Authors:  Raja K Sivamani; Heidi Goodarzi; Miki Shirakawa Garcia; Siba P Raychaudhuri; Lisa N Wehrli; Yoko Ono; Emanual Maverakis
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

2.  Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas.

Authors:  Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-09

3.  Ustekinumab.

Authors:  Kristian Reich; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-05       Impact factor: 84.694

Review 4.  Psoriasis--new insights into pathogenesis and treatment.

Authors:  Ulrich Mrowietz; Kristian Reich
Journal:  Dtsch Arztebl Int       Date:  2009-01-05       Impact factor: 5.594

5.  Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo.

Authors:  Malgorzata Romanowska; Louise Reilly; Colin N A Palmer; Mattias C U Gustafsson; John Foerster
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

Review 6.  [Treatment of chronic pruritus-what is new?]

Authors:  C Zeidler; M Metz; S Steinke; S Ständer
Journal:  Hautarzt       Date:  2018-08       Impact factor: 0.751

Review 7.  Chronic Pruritus: Current and Emerging Treatment Options.

Authors:  Manuel P Pereira; Sonja Ständer
Journal:  Drugs       Date:  2017-06       Impact factor: 11.431

8.  Definition of treatment goals for moderate to severe psoriasis: a European consensus.

Authors:  U Mrowietz; K Kragballe; K Reich; P Spuls; C E M Griffiths; A Nast; J Franke; C Antoniou; P Arenberger; F Balieva; M Bylaite; O Correia; E Daudén; P Gisondi; L Iversen; L Kemény; M Lahfa; T Nijsten; T Rantanen; A Reich; T Rosenbach; S Segaert; C Smith; T Talme; B Volc-Platzer; N Yawalkar
Journal:  Arch Dermatol Res       Date:  2010-09-21       Impact factor: 3.017

9.  Kochia scoparia Saponin Momordin Ic Modulates HaCaT Cell Proliferation and Apoptosis via the Wnt/β-Catenin Pathway.

Authors:  Meijunzi Luo; Bijun Zeng; Haizhen Wang; Zhibo Yang; Youhua Peng; Yujin Zhang; Chang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-16       Impact factor: 2.629

10.  Self-management in daily life with psoriasis: an integrative review of patient needs for structured education.

Authors:  Gitte Susanne Rasmussen; Helle Terkildsen Maindal; Kirsten Lomborg
Journal:  Nurs Res Pract       Date:  2012-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.